Halozyme Therapeutics, Inc.

As of June 30, 2026, Halozyme Therapeutics, Inc. carries a market capitalization of 7.83B, placing it among publicly traded companies globally. Its enterprise value stands at 9.50B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Halozyme Therapeutics, Inc.'s next confirmed earnings release is scheduled for November 9, 2026.

As of June 30, 2026, Halozyme Therapeutics, Inc. has 114.04M shares outstanding.

As of June 30, 2026, Halozyme Therapeutics, Inc. trades at a trailing price-to-earnings ratio of 22.29. The price-to-sales ratio is 5.54, and the price-to-book ratio stands at 62.28.

As of June 30, 2026, Halozyme Therapeutics, Inc. trades at an EV/EBITDA multiple of 15.25 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 6.53 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 18.18 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Halozyme Therapeutics, Inc. trades at an EV/FCF ratio of 13.23, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 9.50B versus a market cap of 7.83B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Halozyme Therapeutics, Inc. maintains a current ratio of 2.71, meaning it holds 2.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 1,495.48, indicating moderate leverage, while an interest coverage ratio of 35.07 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Halozyme Therapeutics, Inc. posted a return on equity (ROE) of 173.67, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 20.49 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 17.86, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 20.72, useful for judging operating efficiency across full business cycles. The company generates approximately 3.60M in revenue per employee across its workforce of 404.75, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.84 indicates how many times Halozyme Therapeutics, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Halozyme Therapeutics, Inc. recorded 148.58M in income tax expense. That works out to an effective tax rate of 29.10, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 510.60M, leaving 362.02M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

These figures are as of the close on October 22, 2026. The 50-day moving average sits at 95.34, while the 200-day moving average is 70.18.

Over the twelve months ended June 30, 2026, Halozyme Therapeutics, Inc. generated 1.46B in revenue and converted that into 362.02M in net income, yielding earnings per share of 2.99. EBITDA reached 623.21M, while operating income came in at 814.72M.

As of June 30, 2026, Halozyme Therapeutics, Inc. holds 202.20M in cash and equivalents against 1.88B in total debt, resulting in a net debt position of 1.74B. Total book value stands at 125.64M, with working capital of 515.19M providing operational flexibility.

Halozyme Therapeutics, Inc. produced 716.52M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -10.83M in capital expenditures, free cash flow totaled 705.69M - equivalent to 6.00 per share.

Over the twelve months ended June 30, 2026, Halozyme Therapeutics, Inc. posted a gross margin of 82.42, reflecting its pricing power and cost economics. The operating margin of 55.95 and net profit margin of 24.86 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield stands at 8.50, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 1.24, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Halozyme Therapeutics, Inc. shareholders.

As of June 30, 2026, Halozyme Therapeutics, Inc. has an Altman Z-Score of 7.47, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.